Network features suggest new hepatocellular carcinoma treatment strategies

BMC Systems Biology
|July 30, 2014
PubMed
Abstract

Insights

Cancer therapy often fails due to drug resistance. This study reveals that targeting immune pathways alongside Sorafenib may overcome hepatocellular carcinoma (HCC) resistance by addressing network redundancy.

Area of Science:

  • Oncology
  • Computational Biology
  • Systems Biology

Background:

  • Therapy resistance is a primary driver of cancer treatment failure.
  • Understanding cancer's robust cellular network and therapy-resistance mechanisms is crucial.
  • Cancer cells exhibit redundancy, enabling survival in stressful environments and resistance to single-target therapies.

Purpose of the Study:

  • To develop a computational method for studying network redundancy and predicting pathway communication.
  • To analyze gene expression data in hepatocellular carcinoma (HCC) to understand resistance mechanisms.
  • To identify effective combination therapies for HCC by considering network properties.

Main Methods:

  • Utilized network theory and gene expression profiles from HCC patients.
  • Developed a computational framework analyzing Gene and Pathway Co-expression Networks.
  • Investigated three distinct mechanisms of redundancy in cancer networks.

Main Results:

  • Identified tight regulation of cancer pathways by immune system pathways.
  • Demonstrated significant changes in network connectivity upon targeting immune pathways.
  • Predicted that combining Sorafenib with immune system treatments is more effective for HCC than with other targeted drugs.

Conclusions:

  • Redundancy, a function of network structure, is a major cause of drug resistance in HCC.
  • Integrating redundant variables can lead to new methods for targeting HCC resistance mechanisms.
  • The study provides insights into redundancy mechanisms and their impact on HCC treatments.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K